Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Sepsis

moxifloxacin has been researched along with Sepsis in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (33.33)29.6817
2010's10 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almstead, NG; Arnold, MA; Baird, J; Branstrom, AA; Chen, G; Dumble, M; Gerasyuto, AI; Karp, GM; Narasimhan, J; Peddi, S; Prasad, JVN; Sheedy, J; Smith, S; Wang, J; Weetall, M; Woll, MG; Zhang, N; Zhang, X1
Huang, X; Wang, Y1
He, R; Hu, Y; Huang, Y; Liu, C; Liu, H; Long, J; Wang, Q; Xie, H; Xing, L; Yan, Z; Zheng, W1
Adamzik, M; Dorn, C; Kees, F; Martini, S; Nowak, H; Oesterreicher, ZA; Rahmel, T; Weidemann, C; Zeitlinger, M1
Demir, C; Durmuş, G; Eren, N; Karagöz, A; Kılıç, S; Yeşilyurt, M1
Dwivedi, P; Gupta, PK; Mishra, PR; Rath, SK; Shukla, P; Verma, AK; Yadav, A1
Baud, O; Bidet, P; Bingen, E; Biran, V; Bonacorsi, S; Brunel-Meunier, N; Charriaut-Marlangue, C; Gressens, P; Kitzis, MD; Le Saché, N; Pansiot, J; Pham, H1
Amann, K; Bröcker, EB; Müller, PA; Trautmann, A1
Bach, F; Bloos, F; Bogatsch, H; Brunkhorst, FM; Büchler, MW; Engel, C; Fritz, H; Gründling, M; Jaschinski, U; John, S; Kiehntopf, M; Kollef, MH; Kuhnt, E; Loeffler, M; Ludewig, K; Marx, G; Meier-Hellmann, A; Moerer, O; Nierhaus, A; Oppert, M; Putensen, C; Ragaller, M; Reill, L; Reinhart, K; Riessen, R; Seibel, A; Spies, C; Welte, T; Weyland, A1
Kochanek, M; Michels, G; Shimabukuro-Vornhagen, A; von Bergwelt-Baildon, M1
Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T1
Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D1
Adachi, J; Ghanem, G; Han, XY; Raad, I1
Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S1
Mow, CS; Ochoa, RA1

Reviews

2 review(s) available for moxifloxacin and Sepsis

ArticleYear
[Sepsis. Update 2012].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:31-32

    Topics: Anti-Bacterial Agents; Aza Compounds; Blood Volume; Central Venous Pressure; Drug Therapy, Combination; Empiricism; Fluid Therapy; Fluoroquinolones; Guideline Adherence; Humans; Moxifloxacin; Multiple Organ Failure; Protein C; Quinolines; Recombinant Proteins; Sepsis; Survival Analysis; Systemic Inflammatory Response Syndrome

2012
Deep infection of a total knee implant as a complication of disseminated pneumococcal sepsis. A case report and review of literature.
    The Knee, 2008, Volume: 15, Issue:2

    Topics: Anti-Infective Agents; Arthroplasty, Replacement, Knee; Aza Compounds; Fluoroquinolones; Humans; Knee Prosthesis; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumococcal Infections; Prosthesis-Related Infections; Quinolines; Reoperation; Sepsis

2008

Trials

1 trial(s) available for moxifloxacin and Sepsis

ArticleYear
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    JAMA, 2012, Jun-13, Volume: 307, Issue:22

    Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Meropenem; Middle Aged; Moxifloxacin; Multiple Organ Failure; Quinolines; Sepsis; Shock, Septic; Survival Analysis; Thienamycins; Treatment Outcome

2012

Other Studies

12 other study(ies) available for moxifloxacin and Sepsis

ArticleYear
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
    Journal of medicinal chemistry, 2018, 05-24, Volume: 61, Issue:10

    Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Protein Conformation; Pyridines; Sepsis; Structure-Activity Relationship; Topoisomerase II Inhibitors

2018
Sepsis after uterine artery embolization-assisted termination of pregnancy with complete placenta previa: A case report.
    The Journal of international medical research, 2018, Volume: 46, Issue:1

    Topics: Abortion, Therapeutic; Adult; Anti-Bacterial Agents; Cesarean Section; Female; Fluoroquinolones; Humans; Moxifloxacin; Placenta Previa; Pregnancy; Sepsis; Serratia Infections; Serratia marcescens; Uterine Artery Embolization; Uterine Hemorrhage

2018
Vibrio vulnificus meningoencephalitis in a patient with thalassemia and a splenectomy.
    Journal of neurovirology, 2019, Volume: 25, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Ceftriaxone; Doxycycline; Humans; Immunocompromised Host; Magnetic Resonance Imaging; Male; Meningoencephalitis; Moxifloxacin; Seafood; Seawater; Sepsis; Splenectomy; Thalassemia; Treatment Outcome; Vibrio vulnificus

2019
Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients.
    The Journal of antimicrobial chemotherapy, 2019, 09-01, Volume: 74, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Biological Availability; Drug Monitoring; Extracellular Fluid; Female; Humans; Male; Middle Aged; Moxifloxacin; Muscles; Sepsis; Subcutaneous Tissue; Tissue Distribution

2019
[A severe cutaneous anthrax case complicated with sepsis in Bursa, Turkey].
    Mikrobiyoloji bulteni, 2013, Volume: 47, Issue:3

    Topics: Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Debridement; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillin G; Quinolines; Sepsis; Sheep; Skin Diseases, Bacterial; Turkey; Wounds and Injuries; Zoonoses

2013
Moxifloxacin-loaded nanoemulsions having tocopheryl succinate as the integral component improves pharmacokinetics and enhances survival in E. coli-induced complicated intra-abdominal infection.
    Molecular pharmaceutics, 2014, Dec-01, Volume: 11, Issue:12

    Topics: Animals; Escherichia coli; Fluoroquinolones; Interleukin-6; Intraabdominal Infections; Male; Moxifloxacin; Rats; Sepsis; Tumor Necrosis Factor-alpha

2014
Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:7

    Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Aza Compounds; Cefotaxime; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Leukoencephalopathies; Moxifloxacin; Quinolines; Rats; Rats, Sprague-Dawley; Sepsis

2011
[Maculo-papular exanthem with acute renal failure. Drug-induced hypersensitivity syndrome].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2012, Volume: 63, Issue:3

    Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aortic Valve; Aza Compounds; Biopsy; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Endocarditis, Bacterial; Eosinophilia; Fluoroquinolones; Glucocorticoids; Humans; Kidney; Legionnaires' Disease; Male; Meropenem; Moxifloxacin; Nephritis, Interstitial; Quinolines; Sepsis; Skin; Thienamycins; Vancomycin

2012
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
    Stroke, 2004, Volume: 35, Issue:1

    Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome

2004
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:2

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome

2005
Central venous catheter-related Streptomyces septic thrombosis.
    Infection control and hospital epidemiology, 2007, Volume: 28, Issue:5

    Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Catheterization, Central Venous; Fluoroquinolones; Humans; Male; Minocycline; Moxifloxacin; Quinolines; Sepsis; Streptomyces; Treatment Outcome; Venous Thrombosis

2007
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:6

    Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Critical Illness; Female; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Multiple Organ Failure; Ofloxacin; Quinolines; Renal Dialysis; Sepsis

2006